Background Tofacitinib is an oral JAK inhibitor for the treatment of adults with ankylosing spondylitis (AS). Objectives To describe tofacitinib safety profile from integrated analysis randomised controlled trials (RCTs) in patients (pts) active AS. Methods Pooled data Phase (P)2 ( NCT01786668 ) and P3 NCT03502616 RCTs pts AS were analysed 3 cohorts (Table 1): 16-Week (Wk) placebo (PBO)-control...